Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
474.57
+4.29 (+0.91%)
Official Closing Price
Updated: 4:15 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Will the Biotech sector sustain its momentum in 2024?
January 04, 2024
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.
Via
MarketBeat
Topics
ETFs
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High
January 03, 2024
Via
Investor Brand Network
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading
December 13, 2023
Via
Investor Brand Network
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
CRISPR Therapeutics sets sights on gene-editing cures for disease
December 27, 2023
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for
Via
MarketBeat
Exposures
Product Safety
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
December 18, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
December 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
December 13, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Nancy Thornberry to its Board of Directors
December 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
November 23, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
InvestorNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’
November 16, 2023
Via
Investor Brand Network
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Why you can make Vertex Pharmaceuticals a buy on any pullback
November 08, 2023
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely
Via
MarketBeat
Exposures
COVID-19
Vertex Reports Third Quarter 2023 Financial Results
November 06, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
November 02, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at Upcoming Investor Conferences
October 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Tuesday Session
October 17, 2023
Via
Investor Brand Network
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Friday Session
October 13, 2023
Via
Investor Brand Network
Vertex to Announce Third Quarter 2023 Financial Results on November 6
October 10, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Michel Lagarde to its Board of Directors
October 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
October 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
September 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
September 14, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
August 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.